+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cervical Cancer Diagnostics And Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

  • PDF Icon


  • 130 Pages
  • August 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 4472804
UP TO OFF until Mar 31st 2024
The Global Cervical Cancer Diagnostics and Therapeutics Market size is expected to grow from USD 95.69 billion in 2023 to USD 124.74 billion by 2028, at a CAGR of 5.44% during the forecast period (2023-2028).

The COVID-19 pandemic had a serious impact on cervical cancer diagnosis and treatment. According to the study published in the Diagnostics Journal in April 2022, during the first lockdown in April 2020, the number of tests dropped by 75.5%, after which the number of cases dropped by up to 36.1% in 2021. During the first 24 months of the pandemic, the total volume of tests lost was 49.9%. The percentage of late-stage cervical cancers (stages III-IV) increased by 17%, while the number of newly diagnosed cancers in the outpatient clinic decreased by 45% from the baseline. However, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased and disease screening services have been resumed.

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives towards cervical cancer prevention, the growing prevalence of cervical cancer, increasing awareness regarding early diagnosis, and strong R&D from key players in cervical cancer diagnosis and drugs. For instance, in May 2022, the National Health Mission (NHM) and the Clinton Health Access Initiative launched a training program for gynecologists and nurses in Uttar Pradesh (India) with the goal of detecting cervical cancer cases at an early stage. These kinds of government programs help find and treat cervical cancer early, which is good for market growth.

The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women worldwide. WHO Updates in February 2022 say that cervical cancer is the fourth most common cancer in women around the world, with 604,000 new cases and 342,000 deaths by 2020.In 2020, low- and middle-income countries will account for nearly 90% of new cases and deaths worldwide. As more people use cervical cancer diagnostic tests to find early signs of the disease, the market is likely to grow.

Additionally, the launch of more efficient combination drugs and tests is expected to boost the growth of the cervical cancer diagnostics and therapeutics market. For instance, in September 2021, the US FDA granted accelerated approval to tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. In the same way, in October 2021, the US FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for people with persistent, recurring, or metastatic cervical cancer whose tumors express PD-L1 (CPS 1), as shown by an FDA-approved test.

But in many countries, testing isn't done regularly because of money problems, and the high cost of cancer treatments slows market growth.

Cervical Cancer Diagnostics And Therapeutics Market Trends

The HPV Test Segment is Expected to Hold a Major Market Share Over the Forecast Period

The Papanicolaou test is a cervical screening method that can detect precancerous and cancerous processes in the cervix and colon. Abnormal findings are frequently followed by more sensitive diagnostic procedures and, if necessary, interventions aimed at preventing cervical cancer progression. An HPV test is recommended for women over 30 to detect the virus. The screening aids in detecting precancerous lesions caused by HPV, which can then be removed to prevent the development of invasive cancers.

The major factor driving the segment's growth includes the rising burden of cervical cancer across the world. The disease is more commonly found in females. According to the report of the HPV Center Japan in October 2021, in Japan, approximately 12,785 new cervical cancer cases are diagnosed each year. Cervical cancer is the tenth leading cause of cancer in women in Japan. Cervical cancer is the second most common cancer in Japanese women aged 15 to 44. Therefore, the incidence of cervical cancer is found to increase every year. In most cases, cervical cancer can be prevented through early detection and treatment of abnormal cell changes in the cervix years before the cancer develops. Therefore, with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecast period.

Moreover, increasing product launches in the country boost the market. For instance, in May 2021, Becton, Dickinson, and Company introduced the industry's first self-collection claims for HPV screening, which have been CE marked under the IVD Directive 98/79/EC. Thus, due to the increasing demand for Pap, HPV, and other tests for cancer screening, the market is expected to grow.

Thus, all the aforementioned factors are anticipated to drive segment growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is one of the largest markets for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness of disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer that have increased the reach of insurance coverage for cervical screening tests, especially for low-income women.

Cervical cancer is one of the leading causes of death among women in the United States. According to the American Cancer Society, based on data updated in January 2022 and the estimates for cervical cancer in the United States for 2022, about 14,100 new cases of invasive cervical cancer will be diagnosed. Since there are more cases of cervical cancer in the U.S., the market is likely to grow quickly over the next few years.

Additionally, favorable government policies in the United States are expected to drive the overall market during the forecast period. Updates from the Centers for Disease Control and Prevention in February 2022 say that the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for screening for breast and cervical cancer has helped the market grow in the United States as a whole.Additionally, the month of January has been designated "Cervical Health Awareness Month" by the United States Congress. The National Cervical Cancer Coalition (NCCC) and its many local chapters across the country raise awareness about cervical cancer, HPV disease, and the importance of early detection during the month of January. While NCCC chapters host events throughout the year, Cervical Health Awareness Month is observed in January, and chapters work to raise awareness in their communities.

However, growing product launches by the key market players support the market's growth. For instance, in September 2021, the US FDA granted accelerated approval to tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.

Considering all of this, it seems likely that the studied market will grow in the United States over the next few years.

Cervical Cancer Diagnostics And Therapeutics Industry Overview

The Cervical Cancer Diagnostics and Therapeutics Market is fragmented, competitive, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology. Some of the companies currently dominating the market are Abbott Laboratories, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Qiagen NV, Advaxis Inc., Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Assumptions and market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Favorable Government Initiatives toward Cervical Cancer Prevention
4.2.2 Growing Prevalence of Cervical Cancer and Increasing Awareness Regarding Early Diagnosis
4.2.3 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
4.3 Market Restraints
4.3.1 Economic Constraints in Many Countries to Adopt Regular Testing Procedures
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Diagnostic Test
5.1.1 Pap Smear Test
5.1.2 HPV Test
5.1.3 Colposcopy
5.1.4 Biopsy and Endocervical Curettage
5.1.5 Other Diagnostic Tests
5.2 By Therapeutics
5.2.1 Avastin (Bevacizumab)
5.2.2 Blenoxane (Bleomycin)
5.2.3 Hycamtin (Topotecan Hydrochloride)
5.2.4 Gemcitabine-Cisplatin
5.2.5 Vaccines Gardasil Cevarix
5.2.6 Other Therapeutics
5.3 By End User
5.3.1 Hospitals
5.3.2 Specilty Clinics
5.3.3 Cancer and Radiation Therapy Centers
5.3.4 Diagnostic Centers
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bristol-Myers Squibb Company
6.1.3 GlaxoSmithKline PLC
6.1.4 Merck & Co. Inc.
6.1.5 Pfizer Inc.
6.1.6 Qiagen NV
6.1.7 Advaxis Inc.
6.1.8 Becton, Dickinson and Company
6.1.9 F. Hoffmann-La Roche Ltd.
6.1.10 DYSIS Medical Ltd
6.1.11 The Cooper Companies, Inc.
6.1.12 Arbor Vita Corporation
6.1.13 Zilico ltd

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Advaxis Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • DYSIS Medical Ltd
  • The Cooper Companies, Inc.
  • Arbor Vita Corporation
  • Zilico ltd